TRACK-TBI Precision Medicine Part 3 - Option II
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Cincinnati, Pittsburgh, Salt Lake City, and San Francisco, United StatesSee the 4 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 26 people, planned
- Started
- 2 Jul 2026
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cyclosporine (CsA)
- Placebo
- Record updated
- 22 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Adults (18-65 years of age, inclusive)
- Head injury warranting clinical evaluation with a non-contrast cranial CT based on American College of Emergency Physicians (ACEP) Centers for Disease Control and Prevention (CDC) clinical policy for TBI imaging
- Able to receive investigational product within 24 hours of head injury
- Closest, prior to randomization GCS score of 3 to 12 (motor score < 6)
- Evidence of TBI on imaging, confirmed by:; Evidence of contusion and/or; Evidence of traumatic axonal microvascular injury (TAMVI)
- Initial Glial Fibrillary Acidic Protein (GFAP) blood level ≥ 1000 pg/mL ≤ 15000 pg/mL determined using a for Research Use Only (RUO) assay(s) or an Investigation Use Only (IUO) assay(s)
- Participants able to undergo Magnetic Resonance Imaging (MRI) scans, no contraindications
- Legally Authorized Representative (LAR) willing and able to provide informed consent
- Participant/LAR able to read, speak, and understand English
Who cannot take part
- Bilaterally fixed dilated pupils in the absence of paralytic medications, or evidence of herniation on cranial CT
- Order for comfort care placed prior to enrollment
- Ongoing pre-injury therapy with the Investigational Product (IP), currently receiving immunosuppressive therapy, chemotherapy, or any contraindicated medications (see CsA Drug contraindications/caution table in the Pharmacy Manual)
- Severe polytrauma or previous conditions that would preclude conducting any study activities
- Pre-existing conditions including disabling developmental, neurologic, psychiatric, medical disorder that continues to produce functional disability up to the time of injury; or imminent death based on clinical judgement
- On psychiatric hold (e.g. codes 5150, 5250)
- Current or medical history of any allergic reactions and/or anaphylactic reactions towards cyclosporine (CsA) and cremophor (also known as kolliphor®)
- Any spinal cord injury of grade A to D on the American Spinal Injury Association (ASIA) Impairment Scale
- Primary diagnosis at the enrolling facility of ischemic or hemorrhagic stroke
- Current or medical history of serious chronic viral or fungal infection
- Current or medical history of active mycobacterial infection or anti-tuberculous treatment
- Medical history of human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody
- Current or medical history of nephrectomy, renal dysfunction, significant renal failure, or high-risk for renal failure, defined as:; Creatinine Clearance (CrCl) or estimated Glomerular Filtration Rate (eGFR) (<60 mL/minute/1.73 m2); Major rhabdomyolysis with creatine kinase > 5,000 IU/L
- Current or medical history of hepatic disease (e.g., liver laceration at time of injury with Abbreviated Injury Scale for Liver Lacerations > 1); cirrhosis), or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >3 times the upper limit of normal lab value at the screening/baseline visit
- Any significant disease or disorder (including abnormal laboratory tests) which, in the opinion of the participating site investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study
- Isolated epidural hematoma
- Current enrollment in another interventional study
- Currently pregnant or currently breastfeeding or planning on becoming pregnant in the next 6M
- Current incarceration or in custody
- Body Mass Index (BMI) >35
- Hemodynamic instability, per participating site physician investigator clinical judgement
- Low likelihood of follow up or study compliance, or any other reason, in the opinion of the participating site investigator, the participants should not participate in the study
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- University of Cincinnati Medical CenterCincinnati, United StatesEnrolling by invitation
- University of PittsburghPittsburgh, United StatesEnrolling by invitation
- University of UtahSalt Lake City, United StatesEnrolling by invitation
- University of California San FranciscoSan Francisco, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drug listed below is approved by the U.S. Food and Drug Administration (FDA) but is being used "off-label" in this study. This means that the drug is not currently approved to treat TBI.
The 2 groups in the trial
- Cyclosporine (CsA)Existing treatment, for comparison
Intravenous (IV) injection, 2.5 mg/kg loading dose given over 2 hours, followed by a 3-day (72-hour) constant IV infusion of 5 mg/kg/day.
- Matching PlaceboPlacebo, for comparison
Intravenous (IV) injection of 0.9% NaCl over 74 hours.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Part 3 - Option II
- Criteria questions
- Built from NCT06790095, who can take part
- Record updated
- 22 October 2026